A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

Abstract Background Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC), but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA) researchers reported that most diffuse-type GCs were genomically stable (GS)...

Full description

Bibliographic Details
Main Authors: Hiroshi Fukamachi, Seon-Kyu Kim, Jiwon Koh, Hye Seung Lee, Yasushi Sasaki, Kentaro Yamashita, Taketo Nishikawaji, Shu Shimada, Yoshimitsu Akiyama, Sun-ju Byeon, Dong-Hyuck Bae, Keisuke Okuno, Masatoshi Nakagawa, Toshiro Tanioka, Mikito Inokuchi, Hiroshi Kawachi, Kiichiro Tsuchiya, Kazuyuki Kojima, Takashi Tokino, Yoshinobu Eishi, Yong Sung Kim, Woo Ho Kim, Yasuhito Yuasa, Shinji Tanaka
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Diffuse-type gastric cancer
mTOR inhibitor
Temsirolimus
PIK3CA
Microsatellite unstable
Immune checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s13046-019-1121-3

Internet

http://link.springer.com/article/10.1186/s13046-019-1121-3

Similar Items